Biora Therapeutics, Inc. Common Stock
BIOR
BIOR was delisted on the 10th of December, 2024.
26 hedge funds and large institutions have $8.07M invested in Biora Therapeutics, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 6 closing their positions.
5,433% more call options, than puts
Call options by funds: $166K | Put options by funds: $3K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 27 → 26 (-1)
10.21% less ownership
Funds ownership: 44.29% → 34.08% (-10%)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
39% less capital invested
Capital invested by funds: $13.3M → $8.07M (-$5.19M)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$82.5K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$45.1K |
| 3 |
Morgan Stanley
New York
|
+$37.9K |
| 4 |
State Street
Boston,
Massachusetts
|
+$12.6K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$11.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$29.2K |
| 2 |
Jane Street
New York
|
-$19.6K |
| 3 |
CIBC Asset Management
Toronto,
Ontario, Canada
|
-$16.6K |
| 4 |
VF
Virtu Financial
New York
|
-$12K |
| 5 |
Millennium Management
New York
|
-$12K |
BIOR Hedge Fund Activity: Q2 2024 in Review
26 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Biora Therapeutics, Inc. Common Stock (BIOR) for Q2 2024, worth a combined $8.07M — down 39% from $13.3M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BIOR and 5 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $82.5K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $29.2K sold.
- 26 institutional investors held Biora Therapeutics, Inc. Common Stock (BIOR) as of Q2 2024, down from 27 in Q1 2024.
- Funds reported $8.07M of Biora Therapeutics, Inc. Common Stock stock for Q2 2024, down 39% quarter-over-quarter.
- 5 funds opened new Biora Therapeutics, Inc. Common Stock positions in Q2 2024 and 6 closed out, a net change of -1 holder.
- The largest Biora Therapeutics, Inc. Common Stock buyer in Q2 2024 was Vanguard Group, an estimated $82.5K added.
- The largest Biora Therapeutics, Inc. Common Stock seller in Q2 2024 was Bridgeway Capital Management, an estimated $29.2K sold.
Based on aggregated 13F filings for Q2 2024.